What the cardiovascular safety data actually shows
Cardiovasc Diabetol 20:32 Hundertmark MJ, Agbaje OF, Coleman R, George JT, Grempler R, Holman RR, Lamlum H, Lee J, Milton JE, Niessen HG, Rider O, Rodgers CT, Valkovi L, Wicks E, Mahmod M, Neubauer S (2021) Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Steps of the carnitine shuttle system Formation of Acyl-Carnitine: Long-chain fatty acids in the cytosol are activated to acyl-CoA, which then reacts with carnitine in the presence of CPT I to form acyl-carnitine
Decisions about switching therapies, discontinuing medication, or exploring alternatives should be made with medical guidance and ongoing monitoring.
for dossier support, registration assistance, and export supplies.